secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001062822-26-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q4 net loss narrows to $15.5M; cash strengthened with $106.7M added in Feb 2026
--------------------------------------------------------------------------------

- Q4 net loss $15.5M ($0.04/share) vs $33.8M loss ($0.09/share) in Q4 2024; full-year loss $50.3M.
- Q4 revenue $5.5M including $4.3M licensing from Novo Nordisk and $1.1M INPEFA sales.
- Cash, investments, restricted cash $125.2M at Dec 31, 2025; $96.7M capital raise + $10M Novo milestone in Feb 2026.
- SONATA-HCM enrollment >50% of 500 patients; on track for mid-2026 completion and Q1 2027 topline.
- NDA resubmission for ZYNQUISTA in T1D on track for 2026; positive End-of-Phase 2 meeting for pilavapadin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000047/0001062822-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000047/lxrx-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001062822-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer